155 results
8-K
EX-10.2
TXMD
TherapeuticsMD Inc
5 Dec 22
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
7:31am
Information” means marketing, advertising, and promotional and similar information, including sales and customer information, that is existing, owned … or any Ancillary Agreement, from and after the NDA Transfer Date, Purchaser (i) shall be responsible for handling and responding to all customer
8-K
EX-10.1
TXMD
TherapeuticsMD Inc
5 Dec 22
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
7:31am
and reasonably incurred by Mayne, its sublicensees or any of their respective Affiliates selling such Products:
(a) customer directed commissions
SC TO-T/A
kzwnkwtyn4xh9w
6 Jul 22
Third party tender offer statement (amended)
6:23am
SC TO-T/A
EX-99
z6lvioy3h
23 Jun 22
Third party tender offer statement (amended)
4:07pm
SC TO-T/A
2n1l2nvom310xp4pmh
23 Jun 22
Third party tender offer statement (amended)
4:07pm
8-K
EX-10.2
d96h22mqjr1 ce
31 May 22
TherapeuticsMD and EW Healthcare Partners
6:47am
8-K
EX-2.1
gw05le2e
31 May 22
TherapeuticsMD and EW Healthcare Partners
6:47am
8-K
EX-99.1
ccb4 46vkihglgg9
20 May 22
Regulation FD Disclosure
10:30am
POS AM
agx6 kozsl0
23 Mar 22
Prospectus update (post-effective amendment)
6:06pm
POSASR
9d39ulpwc q4pir08
23 Mar 22
Automatic shelf registration (post-effective amendment)
4:37pm
8-K
EX-2.1
3xu2hka21duojyf
10 Mar 22
TherapeuticsMD Announces Fourth Quarter 2021 Financial Results
7:15am
SC TO-I
EX-99
vzavuck
26 Aug 21
Issuer tender offer statement
4:55pm